viropharma incorporated pharmaceutical company developed sold drugs addressed serious diseases treated physician specialists hospital settings company focused product development activities viruses human disease including caused cytomegalovirus cmv hepatitis c virus hcv infections purchased shire shire paying around billion company deal finalized january viropharma member nasdaq biotechnology index sp company strategic relationships glaxosmithkline scheringplough sanofiaventis viropharma acquired lev pharmaceuticals merger viropharma incorporated founded claude h nash chief executive officer mark mckinlay vice president research development marc collett vice president discovery research johanna griffin vice president business development guy diana vice president chemistry research none founders still company november shire plc acquired viropharma vancocin pulvules hcl licensed eli lilly oral vancocin antibiotic treatment staphylococcal enterocolitis antibiotic associated pseudomembranous colitis caused clostridium difficile maribavir oral antiviral drug candidate licensed glaxosmithkline prevention treatment human cytomegalovirus disease hematopoietic stem cellbone marrow transplant patients february viropharma announced united states food drug administration fda granted company fast track status march company announced phase ii study maribavir demonstrated prophylaxis maribavir displays strong antiviral activity measured statistically significant reduction rate reactivation cmv recipients hematopoietic stem cellbone marrow transplants intenttotreat analysis first days transplant number subjects required preemptive anticmv therapy statistically significantly reduced pvalue maribavir groups compared placebo group placebo vs maribavir mg twice daily mg daily mg twice daily respectively viropharma conducted phase iii clinical study evaluate prophylactic use prevention cytomegalovirus disease recipients allogeneic stem cell transplant patients february viropharma announced phase iii study failed achieve goal showing significant difference maribavir placebo reducing rate cmv oral pleconaril viropharmas first compound licensed sanofi pleconaril active viruses picornavirus family viropharmas first indication enteroviral meningitis indication abandoned clinical trials demonstrate efficacy viropharma submitted new drug application pleconaril fda common fda antiviral advisory committee recommended company failed show adequate safety fda subsequently issued notapprovable november viropharma licensed pleconaril developing intranasal formulation common cold asthma exacerbations scheringplough development pipeline august scheringplough started phase ii clinical trial httpsenwikipediaorgwikiviropharma